ADT1103-Brazikumab Biosimilar-(IL23A)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1103 |
Product Name |
ADT1103-Brazikumab Biosimilar-(IL23A)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-IL13a antibody, anti IL13a antibody, recombinant IL13a, IL13a antibody, anti-IL13a monoclonal antibody, IL13a antibodies, IL13a recombinant antibody, IL13a blocking antibody
|
|
Alias |
AMG-139, MEDI2070 |
Host |
CHO Cells |
Species |
Human |
Target |
IL23A |
Gene ID |
51561 |
Isotype |
IgG2 Lambda |
Size |
1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1610353-18-8 |
Product Description |
Brazikumab (INN, development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease. This drug was developed by MedImmune. |
Application |
ELISA, IHC, FC, IP, IF, Inhibition, PK |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Oppmann, B., Lesley, R., Blom, B., et al. (2000). “Novel p19 protein engages IL-12p40 to form a cytokine that induces autoimmune inflammation.” The Journal of Experimental Medicine, 192(7), 821-828.
2. Parham, C., et al. (2010). “IL-23 and IL-17 in the pathogenesis of autoimmune disease.” Nature Reviews Immunology, 10(1), 1-12.
3. Langrish, C. L., et al. (2005). “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.” The Journal of Experimental Medicine, 201(2), 233-240.
|





